TransMedics Group, Inc. Common Stock
TMDX
$75.74
+6.33%
TransMedics Group, Inc. is a commercial-stage medical technology company focused on transforming organ transplant therapy through its proprietary Organ Care System (OCS), a portable perfusion, optimization, and monitoring platform designed to preserve donor organs in a near-physiologic state, addressing the limitations of traditional cold storage. The company has established itself as a disruptive innovator and market leader in the organ transplant space, leveraging its technology to expand the pool of viable donor organs and improve transplant outcomes. The current investor narrative is intensely focused on the company's rapid transition to profitability and robust revenue growth, as evidenced by its recent quarterly financials, but this is juxtaposed against significant stock price volatility and a sharp correction from recent highs, raising questions about execution risks and the sustainability of its high-growth, high-margin profile in a capital-intensive healthcare sector.…
TMDX
TransMedics Group, Inc. Common Stock
$75.74
Related headlines
Investment Opinion: Should I buy TMDX Today?
Rating: Hold. The core thesis is that TMDX represents a compelling but risky growth story where exceptional fundamental execution is counterbalanced by severe technical damage and elevated volatility, creating a balanced risk/reward at current levels.
Supporting Evidence: The stock trades at a reasonable trailing P/E of 21.72x given its 32% revenue growth and 31.4% net margin, representing a substantial de-rating from historical multiples above 76x. Analyst consensus projects strong forward EPS of $7.10 on $1.22B revenue, implying continued growth acceleration. The company's financial position is robust with a current ratio of 7.14 and $133.6M in trailing free cash flow, providing operational flexibility. However, the stock's 1.88 beta and 58.76% maximum drawdown highlight extreme volatility that must be priced into any investment decision.
Risks & Conditions: The two biggest risks are growth deceleration below 20% YoY and further multiple compression if the P/E expands back toward historical highs. This Hold rating would upgrade to Buy if the stock establishes a technical base above $90 with improving relative strength, or if quarterly revenue growth accelerates above 35% while maintaining margins. It would downgrade to Sell if the stock breaks below its 52-week low of $60.11 or if quarterly growth decelerates below 15%. Based on current metrics, the stock appears fairly valued relative to its growth profile but overvalued relative to its risk profile.
Sign up to view all
TMDX 12-Month Price Forecast
TMDX presents a classic growth-at-a-reasonable-price dilemma with conflicting signals. Fundamentally, the company is executing exceptionally with 32% revenue growth and a dramatic profitability inflection to 31.4% net margins. However, technically the stock remains in a severe downtrend with extreme volatility (beta 1.88) that has caused 36% annual underperformance versus the market. The current valuation at 21.72x trailing P/E appears reasonable given the growth profile, but the stock lacks catalysts for a near-term re-rating. The stance would upgrade to bullish if the stock can establish sustained momentum above $100 with improving relative strength, or downgrade to bearish if quarterly growth decelerates below 20%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on TransMedics Group, Inc. Common Stock's 12-month outlook, with a consensus price target around $98.46 and implied upside of +30.0% versus the current price.
Average Target
$98.46
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$61 - $98
Analyst target range
Analyst coverage for TMDX appears limited, with only 5 analysts providing estimates for future earnings and revenue, indicating it is likely a mid-cap stock with emerging but not yet broad institutional following; the consensus revenue estimate for the next period is approximately $1.22 billion, with a high estimate of $1.24 billion and a low of $1.20 billion, showing a relatively tight range and high confidence in the top-line growth trajectory. The average EPS estimate is $7.10, ranging from $7.00 to $7.26, implying strong expected profitability, but explicit price targets and a consensus rating are not provided in the data, suggesting analyst opinions may be mixed or in flux. The recent institutional rating actions from firms like Stifel (Hold), Piper Sandler (Overweight), and Needham (Buy) in early 2026 show a generally positive but cautious stance, with no major downgrades following the stock's sharp decline, which could indicate analysts view the pullback as an overreaction to near-term concerns rather than a fundamental breakdown.
Bulls vs Bears: TMDX Investment Factors
The bull case is strongly supported by fundamental execution, with TMDX delivering exceptional revenue growth of 32% YoY and a dramatic profitability inflection to a 31.4% net margin. However, the bear case is equally compelling on a technical and sentiment basis, with the stock down 36% over the past year and exhibiting extreme volatility (beta 1.88). Currently, the fundamental evidence slightly outweighs the technical damage, as the company's financial performance appears to justify a recovery thesis. The single most important tension in the investment debate is whether the market will reward TMDX's proven hyper-growth and profitability with a re-rating, or if the stock's high volatility and elevated valuation multiples will continue to cap upside as growth inevitably moderates.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue grew 32.18% YoY to $160.8M, continuing a multi-quarter acceleration from $121.6M in Q4 2024. This demonstrates strong commercial adoption of the OCS platform across multiple organ types.
- Dramatic Profitability Inflection: Net income surged to $105.4M in Q4 2025, representing a net margin of 31.43%, a massive improvement from 5.64% in the year-ago quarter. This validates the business model and operating leverage potential.
- Strong Financial Position: The company maintains a robust current ratio of 7.14 and generated $133.6M in trailing free cash flow. This financial strength provides a cushion for continued investment and market expansion.
- Attractive Valuation After De-rating: The trailing P/E of 21.72x represents a significant de-rating from 76.36x at year-end 2024, making the valuation more reasonable given the now-proven profitability. The PEG ratio of 0.051 suggests the stock is undervalued relative to its growth rate.
Bearish
- Severe Technical Downtrend: The stock is down 36.46% over the past year and 38.29% over six months, underperforming the SPY by over 60 percentage points. This indicates sustained selling pressure and broken momentum, with the price currently 49% below its 52-week high.
- High Volatility and Beta Risk: With a beta of 1.88, TMDX is 88% more volatile than the market, as evidenced by its maximum drawdown of -58.76%. This makes the stock unsuitable for risk-averse investors and prone to sharp declines in market downturns.
- Elevated Valuation Multiples: Despite the de-rating, the stock trades at a P/S of 6.83x and EV/Sales of 4.91x, which are elevated for a medical device company. These multiples remain vulnerable to compression if revenue growth decelerates from the current 32% pace.
- Gross Margin Pressure Emerging: Gross margin declined to 58.11% in Q4 2025 from 59.22% in Q4 2024, suggesting potential cost pressures or product mix changes. Sustained margin compression could threaten the high-profitability narrative.
TMDX Technical Analysis
The stock is in a pronounced long-term downtrend, having declined 36.46% over the past year, with a more severe 38.29% drop over the last six months, significantly underperforming the broader market which gained 25.65% over the same period. Trading at a current price of $78.79, the stock sits approximately 49% above its 52-week low of $60.105 but 49% below its 52-week high of $156.00, positioning it in the lower half of its annual range and suggesting it has experienced a substantial correction from its peak, moving from a momentum-driven valuation to a potential value or recovery candidate, albeit with high volatility as indicated by its beta of 1.88. Recent momentum shows a nascent recovery attempt, with the stock up 19.14% over the past month, a sharp positive divergence from its steep 30.83% decline over the last three months; this suggests the stock may be finding a bottom after the severe sell-off that culminated in early May, though it remains deeply oversold on a longer-term basis. Key technical levels are clearly defined, with major resistance at the 52-week high of $156.00 and immediate support at the 52-week low of $60.105; a sustained break above the recent downtrend structure would be needed to signal a trend reversal, while a breakdown below the $60 support could trigger another leg down. The stock's beta of 1.88 indicates it is 88% more volatile than the SPY, which is critical for risk management as it implies amplified moves both up and down, consistent with the observed price action and maximum drawdown of -58.76%.
Beta
1.88
1.88x market volatility
Max Drawdown
-58.8%
Largest decline past year
52-Week Range
$60-$156
Price range past year
Annual Return
-32.7%
Cumulative gain past year
| Period | TMDX Return | S&P 500 |
|---|---|---|
| 1m | +3.9% | +1.0% |
| 3m | -34.5% | +7.9% |
| 6m | -46.6% | +8.5% |
| 1y | -32.7% | +20.1% |
| ytd | -38.3% | +9.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMDX Fundamental Analysis
TransMedics is demonstrating explosive revenue growth, with Q4 2025 revenue of $160.76 million representing a 32.18% year-over-year increase, continuing a strong multi-quarter acceleration from $121.62 million in Q4 2024; this growth is driven by the commercial adoption of its OCS technology across multiple organ platforms. The company has achieved a remarkable inflection to profitability, reporting net income of $105.38 million in its most recent quarter, translating to a net margin of 31.43%, a dramatic improvement from a net margin of 5.64% in the year-ago quarter; gross margin remains robust at 58.11% for Q4 2025, though it has moderated slightly from 59.22% in Q4 2024, indicating strong pricing power but potential mix or cost pressures. The balance sheet and cash flow position are solid, with a strong current ratio of 7.14, a manageable debt-to-equity ratio of 0.99, and trailing twelve-month free cash flow of $133.59 million; the return on equity of 40.22% is exceptionally high, reflecting efficient use of shareholder capital, though the elevated ROE is partly amplified by financial leverage as indicated by the debt-to-equity ratio.
Quarterly Revenue
$160764000.0B
2025-12
Revenue YoY Growth
+32.18%
YoY Comparison
Gross Margin
58.11%
Latest Quarter
Free Cash Flow
$133589000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMDX Overvalued?
Given the company's positive net income, the primary valuation metric selected is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio stands at 21.72x, while the forward P/E is 23.91x, indicating the market expects earnings to remain relatively stable or grow modestly in the near term, though the slight premium on the forward multiple suggests some anticipated growth. Compared to its own historical valuation, the current trailing P/E of 21.72x is significantly lower than the 76.36x reported at the end of 2024 and the 39.35x from Q3 2025, reflecting a substantial de-rating as the company's profitability has materialized and growth expectations have been recalibrated; this places the stock at a more reasonable level within its own historical band, moving from a speculative growth premium to a valuation more grounded in actual earnings. The stock also trades at a Price-to-Sales ratio of 6.83x and an EV/Sales of 4.91x, which, while elevated for a medical device company, may be justified by its hyper-growth profile and expanding margins, though these multiples remain sensitive to any growth deceleration.
PE
21.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -683x~311x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: TMDX's primary financial risk is valuation compression if growth decelerates from the current 32% pace, given its elevated P/S ratio of 6.83x. While the company has achieved profitability with a 31.4% net margin, this dramatic improvement creates a high bar for future quarters; any margin contraction could significantly impact earnings. Revenue concentration on the OCS platform represents a single-product risk, though expansion across organ types provides some diversification. The debt-to-equity ratio of 0.99 indicates moderate leverage that could amplify downside if operating performance falters.
Market & Competitive Risks: The stock trades at a forward P/E of 23.91x, which remains premium to many medical device peers, leaving it vulnerable to multiple compression in a rising rate environment. With a beta of 1.88, TMDX exhibits extreme sensitivity to broader market movements, having underperformed the SPY by over 60 percentage points in the past year. Competitive disruption represents a constant threat in medical technology, though the company's first-mover advantage with OCS provides some protection. Regulatory headwinds or reimbursement challenges could slow adoption despite the clear clinical benefits.
Worst-Case Scenario: The worst-case scenario involves a combination of growth deceleration below 20%, gross margin compression below 50%, and a broader market sell-off that disproportionately impacts high-beta growth stocks. This could trigger analyst downgrades and institutional selling, driving the stock toward its 52-week low of $60.11, representing a potential 24% decline from the current price of $78.79. Adding in the stock's historical maximum drawdown of -58.76%, a severe bear case could see the stock retest the $50-$55 range, representing a 30-35% downside from current levels if sentiment turns decisively negative.
FAQ
The primary risks are: 1) Valuation compression risk if revenue growth decelerates from 32% given the elevated P/S of 6.83x; 2) Extreme volatility risk with a beta of 1.88 that has caused 58.76% maximum drawdown; 3) Execution risk as the company transitions from hyper-growth to sustainable growth while maintaining 31.4% net margins; and 4) Competitive/regulatory risk in the medical device sector that could slow OCS adoption. The technical risk is particularly acute, with the stock down 36% over the past year and vulnerable to further declines if it breaks below the $60.11 support level.
The 12-month outlook presents three scenarios with associated probabilities. The base case (50% probability) targets $100-$130, assuming revenue growth stabilizes at 25-30% with sustained profitability. The bull case (30% probability) targets $145-$165, requiring growth acceleration above 35% and multiple expansion. The bear case (20% probability) targets $60-$85, triggered by growth deceleration below 20% and technical breakdown. The most likely outcome is the base case, as the company has demonstrated strong execution but faces headwinds from elevated volatility and valuation sensitivity. Analyst consensus EPS of $7.10 supports the base case trajectory if achieved.
TMDX appears fairly valued relative to its growth profile but carries premium risk metrics. The trailing P/E of 21.72x represents a 72% compression from year-end 2024's 76.36x, making it more reasonable given the company's now-proven profitability. Compared to typical medical device companies, the P/S ratio of 6.83x remains elevated but may be justified by the 32% growth rate. The PEG ratio of 0.051 suggests significant undervaluation if growth sustains. Overall, the market is paying a fair price for hyper-growth execution but demanding a risk premium for the stock's extreme volatility and single-product concentration.
TMDX presents a mixed opportunity that depends heavily on investor risk tolerance. For aggressive growth investors, the stock offers exposure to a company with proven 32% revenue growth and dramatic profitability improvement to 31.4% net margins at a reasonable trailing P/E of 21.72x. However, the stock's extreme volatility (beta 1.88) and 36% decline over the past year make it unsuitable for risk-averse investors. The current Hold rating reflects balanced risk/reward, but the stock could become a good buy for those with high risk tolerance if it establishes technical support above $70 while maintaining growth metrics.
TMDX is primarily suitable for long-term investors with a minimum 2-3 year horizon who can withstand significant volatility. The stock's beta of 1.88 makes it poorly suited for short-term trading except for highly experienced technical traders. Long-term investors can potentially benefit from the company's disruptive technology and expanding TAM in organ transplantation, while short-term traders face elevated risk from the stock's 58.76% maximum drawdown history. The lack of a dividend (0% yield) further supports a growth-oriented, long-term holding period to allow the fundamental story to overcome technical volatility.